Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
about
Possible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington's diseaseReinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes.Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease.Multivariate clustering of progression profiles reveals different depression patterns in prodromal Huntington disease.Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/1 mouse model of Huntington's diseaseNovel methods and technologies for 21st-century clinical trials: a review.Triheptanoin improves brain energy metabolism in patients with Huntington diseaseCompensation in Preclinical Huntington's Disease: Evidence From the Track-On HD StudyMolecular Imaging Markers to Track Huntington’s Disease PathologyNeurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysisStatistical Approaches to Longitudinal Data Analysis in Neurodegenerative Diseases: Huntington's Disease as a Model.Phonatory dysfunction as a preclinical symptom of Huntington disease.Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A Decade of the PREDICT-HD StudyA two years longitudinal study of a transgenic Huntington disease monkey.Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational studyNeuroimaging in Huntington's disease.Motivational, proteostatic and transcriptional deficits precede synapse loss, gliosis and neurodegeneration in the B6.HttQ111/+ model of Huntington's disease.Longitudinal Psychiatric Symptoms in Prodromal Huntington's Disease: A Decade of Data.Attempted and successful compensation in preclinical and early manifest neurodegeneration - a review of task FMRI studiesRecent imaging advances in neurology.In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.Peripheral huntingtin silencing does not ameliorate central signs of disease in the B6.HttQ111/+ mouse model of Huntington's diseaseA clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington's diseaseRD-Connect: an integrated platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research.Systemic delivery of P42 peptide: a new weapon to fight Huntington's disease.Amyotrophic lateral sclerosis: cell vulnerability or system vulnerability?Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients.Huntington's disease accelerates epigenetic aging of human brain and disrupts DNA methylation levels.Everyday cognition in prodromal Huntington diseaseThe effect of multidisciplinary rehabilitation on brain structure and cognition in Huntington's disease: an exploratory study.An automated and quantitative method to evaluate progression of striatal pathology in Huntington's disease transgenic mice.A retrospective analysis of hand tapping as a longitudinal marker of disease progression in Huntington's disease.Test-Retest Reliability of Diffusion Tensor Imaging in Huntington's Disease.An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease.Functional connectivity modeling of consistent cortico-striatal degeneration in Huntington's disease.Stem cells for cell replacement therapy: a therapeutic strategy for HD?Digitomotography in Parkinson's disease: a cross-sectional and longitudinal study.The role of the amygdala during emotional processing in Huntington's disease: from pre-manifest to late stage disease.Progressive cognitive deficit, motor impairment and striatal pathology in a transgenic Huntington disease monkey model from infancy to adulthood.Characterising Upper Limb Movements in Huntington's Disease and the Impact of Restricted Visual Cues.
P2860
Q27011417-C3294C5E-7390-43BF-83A7-28FB2EE9BD2FQ27306293-1126C189-ECA0-454D-B635-2CE9736FBA70Q27316866-5636AC0B-4308-401C-BA25-A9CD92D8089AQ27333729-26DBCC9F-D7D2-427A-9F40-53755C05213AQ27334759-DED9927D-8E22-4196-B553-AF2E54F8187DQ27345820-A6465B2D-7B27-4CAE-93FB-63A1BA3307BDQ28388261-8E78C47A-0208-4CBF-ACF6-4F15F6060E41Q28393234-856998BC-5172-4341-A01C-7FDD26C384ABQ29248766-E956728A-F022-42E5-A6AC-2F71EF5B3BCAQ30224292-C37AA4BF-B1D6-4E82-A778-9C6F7B645F98Q30235601-52B01D1B-87C4-428A-9EB4-1130157BE38CQ30425545-F80E474F-77B9-4C4E-9F00-6D9459D15CC4Q30577157-DF6DC404-6358-4C8B-B7B8-1FD59BA7251EQ30577737-77B92A4A-177B-43A6-B5D7-3AADAEBF8E6BQ30631995-2102D778-9713-4C7C-B785-305B26B57BFBQ30834004-2053948D-63C5-4DAD-8C0B-873BE8778682Q30837903-BC1BEF78-103B-4480-9753-C7A5C33E6EE3Q30855262-672A8CDD-F074-4BF0-868F-350050391CF3Q30862037-0A36E3AA-A2EA-4C77-8C6B-276EBFDF4A18Q30916063-0CFF49B6-3876-4EE4-A5AE-7C2BE669A36DQ31028468-B3786D06-938D-4E64-90DB-98760549B367Q33614987-D67CF010-EB1E-4FFA-976D-135EDB62281AQ33929560-D7AC107A-9EAD-4BCA-A06B-29CBBEA02CA4Q34011881-327864C9-B0AC-49D4-AA89-A6AC1CCDC5B2Q34109060-F2481E2E-067C-4BAD-B218-211BE2FD194DQ34369125-B7AF515E-CCB4-42BE-A0BB-1B808AC5F432Q34470414-09A38A9B-596D-4A3B-BD88-CA28895E186CQ34535959-7C022D23-14C7-4EAE-B9D2-264BCD129659Q34861585-6BB35BB4-A7BB-4684-BA79-3DECC3B15621Q35024584-1156FE23-0FC7-4F84-A085-AA0CDDC8162EQ35049775-E01D3C00-711E-4167-A00E-86778C51E0ACQ35101600-DBD757F5-1AF8-4B55-98F2-992EE86A1B2BQ35132652-97A3020D-3479-4A19-80E5-07589FC1E624Q35135962-7B72A6E8-175B-456C-85F8-206F9BE84473Q35222316-C7163E0F-229A-4DFB-B444-90AE631CA8E1Q35250495-1AA8EA57-4760-4420-BB58-480AFBD42E52Q35526097-C5C0519B-F042-4F87-BA4A-E7AF14066699Q35558091-FA7F64D5-F7C9-449E-B4AA-081A4680F3FDQ35597258-8BC27A7C-C425-4DAD-B961-79B92B82B504Q35738853-0E3BDE4C-A4B1-4E31-B317-F8C8B9A4B09B
P2860
Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Predictors of phenotypic progr ...... f 36-month observational data.
@ast
Predictors of phenotypic progr ...... f 36-month observational data.
@en
type
label
Predictors of phenotypic progr ...... f 36-month observational data.
@ast
Predictors of phenotypic progr ...... f 36-month observational data.
@en
prefLabel
Predictors of phenotypic progr ...... f 36-month observational data.
@ast
Predictors of phenotypic progr ...... f 36-month observational data.
@en
P2093
P50
P1433
P1476
Predictors of phenotypic progr ...... f 36-month observational data.
@en
P2093
Beth Borowsky
Raymund A Roos
TRACK-HD Investigators
P304
P356
10.1016/S1474-4422(13)70088-7
P50
P577
2013-05-09T00:00:00Z